Product Description
CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC<5 ppm). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05180240)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: Orphan Drug - Orphan Drug - Pericarditis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cardiol Therapeutics
Company Location: OAKVILLE A6 L6H 0G5
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, Canada, France, Israel, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Pericarditis
Phase 2: Myocarditis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MAVERIC | P3 |
Not yet recruiting |
Pericarditis |
2026-09-21 |
|
| ARCHER | P2 |
Completed |
Myocarditis |
2025-01-31 |
|
| MAvERIC-Pilot | P2 |
Completed |
Pericarditis |
2024-06-15 |